business
Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX)
Key takeaways
- Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX) Muhammad Ali Khalid Tue, June 23, 2026 at 10:06 PM GMT+7 2 min read BSX Boston Scientific Corp.
- On June 12, Matt O’Brien from Piper Sandler reduced the target price on Boston Scientific Corporation (NYSE:BSX) from $90 to $65, resulting in an adjusted upside potential of close to 45% at the current level.
- Earlier on June 3, Marie Thibault from BTIG also reduced the price target on Boston Scientific Corporation (NYSE:BSX) from $80 to $65, and upheld her Buy rating on the stock.
Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX) Muhammad Ali Khalid Tue, June 23, 2026 at 10:06 PM GMT+7 2 min read BSX Boston Scientific Corp. (NYSE:BSX) is one of the 10 oversold stocks offering high upside.
On June 12, Matt O’Brien from Piper Sandler reduced the target price on Boston Scientific Corporation (NYSE:BSX) from $90 to $65, resulting in an adjusted upside potential of close to 45% at the current level.
The analyst retained an Overweight rating on the stock, observing that the shares have significantly declined in light of a slowdown in some key indicators, and the route to reaching the company’s longstanding revenue growth target of 10% or more.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Investing.com
RBC Capital maintains Revolution stock rating on clinical advantage
Investing.com
Cantor Fitzgerald maintains Biogen stock rating on BIIB080 outlook
Investing.com
Piper Sandler raises Dutch Bros stock price target on competition analysis
Investing.com
Piper Sandler raises Seacoast Banking stock price target on capital returns
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop